<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177095</url>
  </required_header>
  <id_info>
    <org_study_id>2019P002608</org_study_id>
    <nct_id>NCT04177095</nct_id>
  </id_info>
  <brief_title>Immune Monitoring to Facilitate Belatacept Monotherapy</brief_title>
  <official_title>Immune Monitoring to Facilitate Belatacept Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Transplant Genomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CareDx</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To determine the utility of novel blood-based immune monitoring tools (Allosure and
           Trugraf) to facilitate belatacept monotherapy.

        -  To determine the percent of belatacept-treated renal transplant patients that can be
           safely converted to belatacept monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine whether renal transplant recipients treated with a belatacept-based
      immunosuppressive regimen can safely be weaned off all non-belatacept immunosuppression
      (mycophenolate, mTORi, prednisone) in a stepwise fashion. To this end, participants will
      undergo monthly &quot;immune monitoring&quot; using the Allosure (dd-cfDNA) and Trugraf (RNA profiling)
      blood tests to determine if they are in a state of immune quiescence. Only patients who are
      deemed to be immune quiescent, will continue to be weaned of non-belatacept
      immunosuppression.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective single-center, single-arm pilot study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of acute rejection</measure>
    <time_frame>24 months</time_frame>
    <description>Biopsy-proven according to Banff 2017 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR</measure>
    <time_frame>24 months</time_frame>
    <description>Calculated using CKD-EPI formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of new-onset proteinuria</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as g/g creatinine, measured on random urine sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of de novo donor specific antibodies</measure>
    <time_frame>24 months</time_frame>
    <description>Screened for using Luminex platform</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Overall and death-censored graft survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Belatacept treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal transplant recipients treated with a combination of belatacept and any of the following: mycophenolate, sirolimus, everolimus and prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Allosure</intervention_name>
    <description>Monthly monitoring of dd-cfDNA levels in blood</description>
    <arm_group_label>Belatacept treated patients</arm_group_label>
    <other_name>donor-derived cell-free DNA (dd-cfDNA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunosuppression reduction</intervention_name>
    <description>Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results</description>
    <arm_group_label>Belatacept treated patients</arm_group_label>
    <other_name>Belatacept</other_name>
    <other_name>mycophenolate</other_name>
    <other_name>sirolimus</other_name>
    <other_name>everolimus</other_name>
    <other_name>prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Trugraf</intervention_name>
    <description>Monthly monitoring of Trugraf result</description>
    <arm_group_label>Belatacept treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age minimum 18 years

          -  Written informed consent

          -  Single kidney transplant recipient (i.e. no combined organ transplants)

          -  Treated with de novo belatacept since transplantation (i.e. no previous use of
             calcineurin inhibitor or mTOR inhibitor for the current transplant)

          -  At least 1 year after transplantation or after initiation of belatacept

          -  Stable renal function (eGFR &gt; 40 ml/min continuously during previous 6 months)

          -  Blood biomarkers indicate immune quiescence (for Allosure this corresponds to dd-cfDNA
             &lt; 1%; for Trugraf this corresponds to &quot;TX&quot; signature)

          -  No history of BK viremia in current allograft

        Exclusion Criteria:

          -  History of biopsy-proven acute rejection

          -  Presence of donor-specific antibodies (at any MFI)

          -  Spot urine protein/creatinine ratio &gt; 0.5 g/g
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannah Gilligan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Vanhove, MD</last_name>
    <phone>6176432257</phone>
    <email>thomasvanhove1987@gmail.com</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Hannah Gilligan</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

